In a tumoral context, delphinidin has been reported to decrease levels of EGF-induced VEGF-A expression in prostate and lung cancer cells, by a mechanism involving the inhibition of HRE-promoter activity in response to EGF induction, and the blockage of ERK and PI3K/Akt pathways [283,284]. This evidence concerns the gene EGF and lung carcinoma.